Heart disease continues to be one of the biggest health threats around the world. For years, aspirin has been the go-to medicine for people with heart disease to help prevent heart attacks and strokes. It works by thinning the blood, making it less likely to form clots that could block blood flow to the heart or brain.
However, aspirin isn’t perfect. While it can save lives, it can also cause serious side effects, especially bleeding. Doctors have long searched for a safer, more effective option—and now, a new study from the Cardiocentro Ticino Foundation in Switzerland may have found one.
The research focused on a group of drugs known as P2Y12 inhibitors, which are often given with aspirin for a short time after a heart attack. These include medications like clopidogrel, prasugrel, and ticagrelor. Scientists wanted to find out whether taking one of these drugs on its own, instead of aspirin, might be a better long-term choice.
To test this, they studied more than 24,000 people with heart disease. Half the participants took aspirin, while the other half took a P2Y12 inhibitor. The researchers followed the participants for about 18 months to see who had another heart attack, a stroke, or serious bleeding.
The results were striking. People who took P2Y12 inhibitors were less likely to have a heart attack or stroke than those who took aspirin. In fact, the overall risk dropped by 12%, and the number of heart attacks was reduced by 23% in the P2Y12 group. That’s a big difference for a condition where even small improvements can save many lives.
But what about bleeding, the side effect that’s often a problem with blood-thinning medications? Surprisingly, the study found that major bleeding was not more common in the P2Y12 group. In fact, serious bleeding in the stomach or brain happened less often in people taking these drugs compared to aspirin.
These results were led by Professor Marco Valgimigli and his team, who believe this could lead to major changes in how doctors treat heart disease. If P2Y12 inhibitors offer better protection and fewer side effects, they could become the new standard treatment—replacing aspirin as the first choice for many patients.
Heart disease is still the number one cause of death in many countries, so improving treatment is vital. This study gives patients and doctors a reason to reconsider the role of aspirin. It also opens the door to using medicines that may offer better results with fewer risks.
Of course, every patient is different, and decisions about treatment should always be made in discussion with a doctor. But with this new evidence, P2Y12 inhibitors could soon play a bigger role in protecting people from life-threatening heart problems—offering a safer, smarter way forward in the fight against heart disease.
If you care about heart health, please read studies that vitamin K helps cut heart disease risk by a third, and a year of exercise reversed worrisome heart failure.
For more health information, please see recent studies about supplements that could help prevent heart disease, stroke, and results showing this food ingredient may strongly increase heart disease death risk.
Copyright © 2025 Knowridge Science Report. All rights reserved.
